Clinical Trial Update: Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluates regorafenib in combination with fulvestrant for recurrent low-grade serous ovarian cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Serous Ovarian Cancer
• Ovarian Cancer
• Serous Ovarian Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Stivarga (regorafenib)

Snippet

Sponsor: Sarah K. Lynam MD | Conditions: Ovarian Cancer, Serous Ovarian Cancer | Phase 2 | Status: RECRUITING